The Hyderabad-based Natco Pharma, to establish its presence in the oncology segment, has launched Letronat 2.5 mg tablets (generic name Letrozole) with an aggressive pricing strategy.
Letrazole, a non-steroidal aromatase inhibitor, is indicated for first-line treatment of advanced breast cancer in post-menopausal women.
This is the third anti-cancer product from the company which had launched Veenat (generic name Imatinib Mesylate) in January and Zoledronic Acid injection about 10 days back for the first time in the country.
The company also has plans to launch two more breakthrough products in the oncology segment in a couple of months.
Though Natco is not the first entrant in the domestic market in the case of Letrozole, the company hopes to attract volumes since its product is priced at Rs 9.90 a tablet against Rs 20 to Rs 30 in case of other domestic brands.
Dr Reddy
